7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 
      
    		                       
      assets
    		                       
      current assets
    		                       
      cash and cash equivalents
    		39,072,000 37,599,000 41,929,000 33,901,000 41,320,000 36,976,000 37,616,000 28,038,000 110,751,000 266,558,000 36,280,000 43,069,000 42,551,000 55,143,000 30,572,000 59,714,000 40,807,000 49,170,000 28,996,000 54,951,000 92,552,000 96,016,000 63,650,000 
      marketable securities, available-for-sale
    		239,219,000 249,041,000 278,373,000  349,932,000 389,409,000 451,368,000  405,886,000 286,428,000 356,239,000  379,175,000 400,078,000 258,797,000  325,984,000 201,730,000   274,884,000 137,175,000  
      marketable equity securities
    		2,406,000 16,791,000 12,151,000 19,174,000                    
      contracts receivable
    		   5,000,000                    
      prepaid expenses and other current assets
    		7,605,000 8,165,000 10,429,000 9,982,000 9,018,000 13,231,000 14,822,000 13,799,000 11,627,000 10,943,000 17,707,000 14,562,000 12,164,000 12,405,000 11,670,000 10,636,000 10,423,000 8,301,000 7,725,000 6,182,000 5,178,000 5,217,000 2,220,000 
      total current assets
    		288,302,000 311,596,000 342,882,000 386,066,000 400,270,000 439,616,000 503,806,000 496,718,000 528,264,000 563,929,000 410,226,000 451,933,000 433,890,000 467,626,000 301,282,000 350,770,000 377,565,000 259,449,000 306,354,000 345,104,000 372,736,000 238,481,000 66,009,000 
      property and equipment
    		2,927,000 3,087,000 3,247,000 4,699,000 5,016,000 5,337,000 5,679,000 5,819,000 6,393,000 6,650,000 6,880,000 7,705,000 8,027,000 8,218,000 8,480,000 8,148,000 4,698,000 2,251,000 1,508,000 1,099,000 471,000 481,000 519,000 
      operating lease right-of-use assets
    		30,188,000 31,175,000 31,925,000 32,528,000 33,403,000 33,474,000 34,726,000 35,916,000 36,184,000 36,584,000 37,475,000 42,373,000 42,646,000 43,305,000 43,644,000 44,691,000 693,000 1,195,000 1,901,000 2,520,000 1,925,000 2,090,000 2,276,000 
      prepaid expenses and other assets
    		3,206,000 3,222,000 3,340,000 4,417,000 5,609,000 6,836,000 6,851,000 6,818,000 8,511,000 7,918,000 9,495,000 9,723,000 10,232,000 11,938,000 10,164,000 7,040,000 6,042,000 4,794,000 2,790,000 2,976,000 4,245,000 3,218,000 2,353,000 
      restricted cash
    		2,627,000 2,627,000 2,627,000 2,627,000 2,627,000 2,681,000 2,681,000 2,681,000 2,627,000 2,627,000 2,627,000    243,000 243,000 243,000 243,000 3,264,000 1,320,000 1,320,000 411,000 411,000 
      total assets
    		327,250,000 351,707,000 384,021,000 430,337,000 450,661,000 491,680,000 557,479,000 551,688,000 585,715,000 621,444,000 489,342,000 539,310,000 529,193,000 567,856,000 405,677,000 454,507,000 435,081,000 283,962,000 328,353,000 365,555,000 393,233,000 257,217,000 87,629,000 
      liabilities and stockholders’ equity
    		                       
      current liabilities
    		                       
      accounts payable
    		7,031,000 3,719,000 7,769,000 7,438,000 8,202,000 20,440,000 10,502,000 14,926,000 14,264,000 12,305,000 12,818,000 11,247,000 9,820,000 12,041,000 13,163,000 11,590,000 8,046,000 8,273,000 8,337,000 8,661,000 5,437,000 4,217,000 7,019,000 
      accrued expenses
    		30,137,000 35,303,000 41,661,000 45,287,000 46,675,000 46,252,000 44,296,000 54,441,000 44,654,000 39,454,000 43,540,000 45,400,000 44,241,000 36,595,000 30,322,000 32,354,000 31,369,000 25,304,000 24,460,000 19,940,000 18,469,000 11,350,000 9,920,000 
      total current liabilities
    		37,168,000 39,022,000 49,430,000 52,725,000 54,877,000 66,692,000 54,798,000 69,367,000 58,918,000 51,759,000 56,358,000 56,647,000 54,061,000 48,636,000 43,485,000 43,944,000 39,415,000 33,577,000 32,797,000 28,601,000 23,906,000 15,567,000 16,939,000 
      long-term lease liability
    		36,708,000 37,690,000 38,651,000 39,577,000 40,457,000 41,318,000 42,616,000 43,150,000 43,266,000 44,027,000 44,771,000 45,166,000    44,459,000        
      other long-term liabilities
    		500,000 500,000 558,000 849,000 996,000 1,089,000 1,294,000 1,780,000 1,634,000 2,376,000 1,792,000 2,620,000 45,169,000 45,072,000 44,978,000   296,000 438,000 1,097,000 1,031,000 1,262,000 1,484,000 
      total liabilities
    		74,376,000 77,212,000 88,639,000 93,151,000 96,330,000 109,099,000 98,708,000 114,297,000 103,818,000 98,162,000 103,677,000 105,286,000 100,455,000 95,033,000 90,011,000 90,025,000 41,085,000 36,353,000 35,715,000 32,178,000 27,400,000 19,292,000 20,886,000 
      commitments and contingencies
    		                       
      equity
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2025 and december 31, 2024
    		                       
      common stock
    		72,000 72,000 72,000 71,000 71,000 71,000 70,000 70,000 70,000 70,000 59,000 59,000 57,000 57,000 46,000 45,000 45,000 41,000 41,000 41,000 41,000 36,000  
      additional paid-in capital
    		1,408,855,000 1,403,912,000 1,397,626,000 1,390,952,000 1,359,589,000 1,349,135,000 1,336,416,000 1,323,576,000 1,309,696,000 1,295,520,000 1,045,568,000 1,031,462,000 972,111,000 961,205,000 734,997,000 723,593,000 702,855,000 529,019,000 519,030,000 509,339,000 501,522,000 339,160,000  
      accumulated other comprehensive income
    		186,000 59,000 358,000  1,594,000 140,000 773,000         -125,000 32,000 94,000 50,000 36,000 23,000 4,000  
      accumulated deficit
    		-1,156,239,000 -1,129,548,000 -1,102,674,000 -1,054,395,000 -1,006,923,000 -966,765,000 -878,488,000 -888,556,000 -827,639,000 -772,111,000 -659,584,000 -596,365,000 -541,394,000 -486,993,000 -418,636,000 -359,559,000 -309,500,000 -305,309,000 -250,735,000 -200,834,000 -160,531,000 -125,976,000 -99,119,000 
      total stockholders’ equity
    		252,874,000 274,495,000 295,382,000  354,331,000 382,581,000 458,771,000  481,768,000 523,141,000 385,487,000  428,504,000 472,490,000 315,298,000  393,432,000 223,845,000      
      total liabilities and stockholders’ equity
    		327,250,000 351,707,000 384,021,000  450,661,000 491,680,000 557,479,000  585,715,000 621,444,000 489,342,000  529,193,000 567,856,000 405,677,000  435,081,000 283,962,000      
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2025 and december 31, 2024
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2025 and december 31, 2024
    		                       
      marketable debt securities, available for sale
    		   318,009,000                    
      goodwill
    		    3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 
      liabilities and stockholders' equity
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2024 and 2023
    		                       
      accumulated other comprehensive income/
    		   558,000    2,194,000                
      total stockholders' equity
    		   337,186,000    437,284,000    433,803,000    363,954,000   268,386,000     
      noncontrolling interests
    		       107,000 129,000 141,000 178,000 221,000 234,000 333,000 368,000 528,000 564,000 23,764,000 24,252,000 24,795,000 24,778,000 24,701,000 6,712,000 
      total equity
    		   337,186,000 354,331,000 382,581,000 458,771,000 437,391,000 481,897,000 523,282,000 385,665,000 434,024,000 428,738,000 472,823,000 315,666,000 364,482,000 393,996,000 247,609,000 292,638,000 333,377,000 365,833,000 237,925,000  
      total liabilities and stockholders' equity
    		   430,337,000    551,688,000    539,310,000    454,507,000        
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2024 and december 31, 2023
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2024 and december 31, 2023
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2024 and december 31, 2023
    		                       
      marketable securities, available for sale
    		       454,881,000    394,302,000    280,173,000   269,385,000 283,554,000    
      investment in zentera therapeutics
    		          18,903,000 21,213,000 28,035,000 30,406,000 35,744,000 37,495,000 39,326,000       
      deferred tax liability
    		          756,000 853,000 1,225,000 1,325,000 1,548,000 1,622,000 1,670,000 2,480,000 2,480,000 2,480,000 2,463,000 2,463,000 2,463,000 
      preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2023 and 2022
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2023 and december 31, 2022
    		                       
      accumulated other comprehensive loss
    		        -359,000 -338,000 -556,000 -1,353,000 -2,270,000 -1,779,000 -1,109,000         
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2023 and december 31, 2022
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2023 and december 31, 2022
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2022 and 2021
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2022 and december 31, 2021
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2022 and december 31, 2021
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2022 and december 31, 2021
    		                       
      accounts receivable from government grants
    		               4,000 108,000 5,000 248,000 417,000 122,000 73,000 139,000 
      in-process research and development
    		                 8,800,000 8,800,000 8,800,000 8,800,000 8,800,000 8,800,000 
      preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2021 and 2020
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2021 and december 31, 2020
    		                       
      deferred financing costs
    		                 716,000     3,525,000 
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2021 and december 31, 2020
    		                       
      liabilities, convertible preferred units and equity
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at march 31, 2021 and december 31, 2020
    		                       
      total liabilities and equity
    		                  328,353,000     
      convertible preferred units; redemption value of 146,944 at december 31, 2019
    		                       
      class a common units; 20,000,000 units authorized at december 31, 2019; 5,601,478 units issued and outstanding at december 31, 2019
    		                       
      class b common units 3,458,522 units authorized at december 31, 2019; 2,670,668 units issued and outstanding at december 31, 2019
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at december 31, 2020
    		                       
      total stockholders' equity/members'
    		                   308,582,000    
      total liabilities, convertible preferred units and equity
    		                   365,555,000 393,233,000 257,217,000  
      liabilities, convertible preferred units and equity/
    		                       
      convertible preferred units; redemption value of 146,944,000 at december 31, 2019
    		                       
      class a common units; 20,000,000 units authorized; 5,601,478 units issued and outstanding at december 31, 2019
    		                       
      class b common units, 3,458,522 units authorized; 2,670,668 units issued and outstanding at december 31, 2019
    		                       
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2020
    		                       
      total stockholders’ equity/members’
    		                    341,055,000 213,224,000  
      preferred stock, 0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2020
    		                       
      liabilities, convertible preferred units and deficit
    		                       
      convertible preferred units; redemption value of 162,120,000 and 146,944,000 at march 31, 2020 and december 31, 2019, respectively
    		                      155,934,000 
      class a common units; 20,000,000 units authorized at march 31, 2020 and december 31, 2019; 5,601,478 units issued and outstanding at march 31, 2020 and december 31, 2019
    		                      709,000 
      class b common units, 3,458,522 units authorized at march 31, 2020 and december 31, 2019; 2,607,309 and 2,670,668 units issued and outstanding at march 31, 2020 and december 31, 2019, respectively
    		                      2,507,000 
      total zentalis pharmaceuticals, llc members’ deficit
    		                      -95,903,000 
      total deficit
    		                      -89,191,000 
      total liabilities, convertible preferred units and deficit
    		                      87,629,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.